Inovio Pharmaceuticals, Inc.

NasdaqCM:INO Stock Report

Market Cap: US$202.4m

Inovio Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Inovio Pharmaceuticals's earnings have been declining at an average annual rate of -10.2%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 23.6% per year.

Key information

-10.2%

Earnings growth rate

9.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-23.6%
Return on equity-132.3%
Net Margin-17,423.5%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio: After All These Years

Jul 19

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Apr 15

Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Mar 21
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Inovio Undervalued On Potential 2022 Catalyst

Jan 26

Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Dec 31
Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio: Simply Cannot Be Ignored

Sep 03

Inovio Has 4 Sources Of Potential Value

Jun 23

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Jun 11
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio stock trades higher defying insider sale

Jun 07

Revenue & Expenses Breakdown

How Inovio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:INO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241-125450
31 Dec 231-135480
30 Sep 231-165360
30 Jun 2310-168380
31 Mar 2310-241730
31 Dec 2210-280760
30 Sep 2211-332900
30 Jun 222-355920
31 Mar 222-328560
31 Dec 212-304540
30 Sep 217-221480
30 Jun 216-142450
31 Mar 216-188440
31 Dec 207-166370
30 Sep 202-180370
30 Jun 203-222330
31 Mar 203-123280
31 Dec 194-119270
30 Sep 196-115240
30 Jun 197-117250
31 Mar 1932-94270
31 Dec 1830-97290
30 Sep 1837-86320
30 Jun 1837-95310
31 Mar 1833-97300
31 Dec 1742-88280
30 Sep 1742-93270
30 Jun 1752-80270
31 Mar 1738-89260
31 Dec 1635-74240
30 Sep 1633-65220
30 Jun 1644-39200
31 Mar 1644-27190
31 Dec 1541-29180
30 Sep 1537-19170
30 Jun 1515-31160
31 Mar 1513-36160
31 Dec 1410-36160
30 Sep 1410-44160
30 Jun 1417-68160
31 Mar 1414-68150
31 Dec 1313-66140
30 Sep 1313-51120
30 Jun 134-27120

Quality Earnings: INO is currently unprofitable.

Growing Profit Margin: INO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: INO has a negative Return on Equity (-132.29%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.